SPRINGWORKS THERAPEUTICS, INC. (SWTX) News
Filter SWTX News Items
SWTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SWTX News Highlights
- SWTX's 30 day story count now stands at 6.
- Over the past 16 days, the trend for SWTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ROSE, CONN and RARE are the most mentioned tickers in articles about SWTX.
Latest SWTX News From Around the Web
Below are the latest news stories about SPRINGWORKS THERAPEUTICS INC that investors may wish to consider to help them evaluate SWTX as an investment opportunity.
How did SpringWorks Therapeutics Inc. (SWTX) fare last session?The share price of SpringWorks Therapeutics Inc. (NASDAQ:SWTX) rose to $28.09 per share on Tuesday from $27.55. While SpringWorks Therapeutics Inc. has overperformed by 1.96%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWTX fell by -48.21%, with highs and lows ranging from $65.92 to $13.60, […] |
SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Lose -4.03%, Marking A Loss For Bears.In the last trading session, 1.31 million SpringWorks Therapeutics Inc. (NASDAQ:SWTX) shares changed hands as the company’s beta touched 0.57. With the company’s per share price at $26.41 changed hands at -$1.11 or -4.03% during last session, the market valuation stood at $1.65B. SWTX’s last price was a discount, traded about -149.6% off its 52-week … SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Lose -4.03%, Marking A Loss For Bears. Read More » |
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare ConferenceSTAMFORD, Conn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, will present today at the 41st Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET), and a live webcast will be available at ir.springworkstx.com. Ahead of the presentation, the Company highlighted its 2022 accomplishments and announced its a |
Can you still get a good price for SpringWorks Therapeutics Inc. (SWTX) Shares at this point?A share of SpringWorks Therapeutics Inc. (NASDAQ:SWTX) closed at $28.43 per share on Wednesday, up from $26.27 day before. While SpringWorks Therapeutics Inc. has overperformed by 8.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWTX fell by -56.57%, with highs and lows ranging from $65.92 […] |
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceSTAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT. |
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid TumorsSTAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors. |
SpringWorks seeks FDA approval of nirogacestat for desmoid tumorsSpringWorks Therapeutics (SWTX) completed the submission of a new drug application ((NDA)) to the U.S |
SpringWorks Therapeutics Inc. (NASDAQ: SWTX): Can A Stock Be -62.42% Lower Year-To-Date And Still Be A Loser?SpringWorks Therapeutics Inc. (NASDAQ:SWTX)’s traded shares stood at 0.78 million during the last session. At the close of trading, the stock’s price was $23.29, to imply a decrease of -1.48% or -$0.35 in intraday trading. The SWTX share’s 52-week high remains $72.20, putting it -210.0% down since that peak but still an impressive 41.61% since … SpringWorks Therapeutics Inc. (NASDAQ: SWTX): Can A Stock Be -62.42% Lower Year-To-Date And Still Be A Loser? Read More » |
Have you been able to find a good deal on SpringWorks Therapeutics Inc.’s shares?In Wednesday’s session, SpringWorks Therapeutics Inc. (NASDAQ:SWTX) marked $24.18 per share, up from $23.51 in the previous session. While SpringWorks Therapeutics Inc. has overperformed by 2.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWTX fell by -66.35%, with highs and lows ranging from $74.97 to […] |
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx ConferenceSTAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET. To access the live webcast please visit the Events & Presentations pag |